EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study

Yingxiao Cai, Wu Wen, Yangshuo Xia, Renhua Wan iD

Current Oncology · 2025

DOI: 10.3390/curroncol32020087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Yingxiao Cai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Nanchang University, No. 17 Yongwaizheng Street, Donghu District, Nanchang 330006, Ch…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Phenylurea Compounds, Quinolines, Bile Duct Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Although systemic chemotherapy (SC) is the mainstay for treating unresectable intrahepatic cholangiocarcinoma (ICC), its efficacy is limited and it causes severe systemic side effects. This study focuses on evaluating the effectiveness and safety of hepatic arterial infusion chemotherapy (HAIC) in combination with lenvatinib plus programmed death-1 (PD-1) inhibitors (HLP), compared to SC in combination with lenvatinib plus PD-1 inhibitors (SCLP) for unresectable ICC.

Methods

We analyzed patients initially diagnosed with unresectable ICC at our center between March 2021 and December 2023, classifying them into HLP and SCLP groups according to treatment regimen. This study assessed and compared overall survival (OS), progression-free survival (PFS), tumor response, and safety outcomes across the two treatment groups.

Results

This study enrolled 53 subjects in total; 25 were treated with HLP and 28 with SCLP. The two groups showed well-matched baseline characteristics. The HLP group reported an extended median OS (12.8 vs. 11.0 months, p = 0.310) and a prolonged median PFS (8.8 vs. 6.4 months, p = 0.043), compared to the SCLP group. The HLP group had a better objective response rate (ORR) (52% vs. 25%, p = 0.043) and disease control rate (DCR) (96% vs. 78.6%, p = 0.104). Based on OS (p = 0.019) and PFS (p = 0.032) results, those without extrahepatic metastasis seemed to benefit more significantly from the HLP regimen than from the SCLP regimen. The HLP group experienced fewer grade 3–4 adverse events (AEs) than the SCLP group.

Conclusions

The HLP regimen for unresectable ICC is an effective and safe strategy and is potentially better suited for patients without extrahepatic metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaPhenylurea CompoundsQuinolinesBile Duct NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedInfusions, Intra-ArterialHepatic ArteryAdult

Stichwörter der Autor:innen

PD-1 inhibitorshepatic artery infusion chemotherapylenvatiniboverall survivalunresectable intrahepatic cholangiocarcinoma

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of General Surgery, The First Affiliated Hospital of Nanchang University, No. 17 Yongwaizheng Street, Donghu District, Nanchang 330006, China.

ORCID-Profile: Renhua Wan

Zitieren

APA

Cai, Y., Wen, W., Xia, Y., & Wan, R. (2025). The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study. Current Oncology. https://doi.org/10.3390/curroncol32020087

Vancouver

Cai Y, Wen W, Xia Y, Wan R. The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study. Current Oncology. 2025. doi:10.3390/curroncol32020087

BibTeX
@article{Cai2025,
  author = {Cai, Yingxiao and Wen, Wu and Xia, Yangshuo and Wan, Renhua},
  title = {The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32020087}
}
Kostenlos starten →